Phase 2 Trials Begin Dosing Patients with SHR0302, Reistone’s Investigational JAK1 Inhibitor
News
The first patients with ulcerative colitis (UC) and Crohn’s disease (CD) have been dosed in two Phase 2 trials assessing the effects of SHR0302, Reistone Biopharma‘s investigational drug for the ... Read more